(firstQuint)Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease.

 This is a 16-week, Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group design study in male and female subjects with mild to moderate Alzheimers disease (AD).

 Subjects will undergo 2-week placebo run-in period before randomisation.

 They will undergo weekly review of safety, tolerability and cognitive performance measures.

.

 Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease@highlight

This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with mild to moderate Alzheimer's disease